BPI-585771
/ Betta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BPI-585771: A novel, potent pan-KRAS degrader with potent in vitro and in vivo efficacy in KRAS-driven tumors
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Preclinical • Oncology • KRAS
1 to 1
Of
1
Go to page
1